BrainsWay completes revenue-based milestone investment into Axis Integrated Mental Health — mental health TMS network expansion
Summary
BrainsWay completed a revenue-based milestone investment into Axis Integrated Mental Health in early 2026, as reported in Neurotech Notables #51. The investment follows BrainsWay's $6M milestone investment in Neurolief after Proliv Rx's FDA PMA approval. Axis Integrated Mental Health is a US mental health clinic network that uses Deep TMS therapy for OCD, depression, and other conditions. The revenue-based structure — where BrainsWay's investment return is tied to Axis's clinical revenue — creates aligned incentives for clinic growth and deep TMS procedure volume. BrainsWay's strategy of investing in clinic networks that use their devices is a novel device company commercial model.
Why it matters
BrainsWay investing in clinical networks that use their devices — revenue-based, aligned with procedure volume — is a differentiated commercial model compared to standard device sales. Rather than solely competing on device pricing against Neurostar and Mag Venture, BrainsWay is building a vertically integrated TMS clinic ecosystem where the device company captures economics from both device sales and clinic revenue. If successful, this model could significantly increase BrainsWay's per-patient revenue capture.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial